<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Asthma in children younger than 12 years: Quick-relief (rescue) treatment for acute symptoms</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Asthma in children younger than 12 years: Quick-relief (rescue) treatment for acute symptoms</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Asthma in children younger than 12 years: Quick-relief (rescue) treatment for acute symptoms</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gregory Sawicki, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenan Haver, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert A Wood, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gregory Redding, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Quick-relief (also called rescue or acute symptom relief) medications are primarily taken to relieve the bronchoconstriction that occurs with acute asthma symptoms (eg, wheeze, cough, chest tightness, shortness of breath), although some agents may have additional effects. Quick-relief agents include short-acting beta agonists (SABAs), rapid-onset long-acting beta agonists (LABAs) either alone or in combination with an inhaled glucocorticoid, and an anticholinergic bronchodilator (eg, <a class="drug drug_pediatric" data-topicid="13389" href="/z/d/drug information/13389.html" rel="external">ipratropium</a> bromide) alone or in combination with a SABA.</p><p>Medications initiated by the patient/caregiver for the quick relief of asthma symptoms in children younger than 12 years of age are reviewed here. The recommendations below are based upon National Asthma Education and Prevention Program (NAEPP) expert panel guidelines published in 2007 [<a href="#rid1">1</a>] and updated in 2020 [<a href="#rid2">2</a>] and Global Initiative for Asthma (GINA) 2020 guidelines [<a href="#rid3">3</a>], which are similar to other major published asthma guidelines. (See <a class="local">'Society guideline links'</a> below.)</p><p>Home management of more significant symptoms associated with an asthma exacerbation are reviewed in detail separately. The outpatient and hospital management of acute asthma exacerbations in children are also discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/91328.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Overview of home/office management and severity assessment"</a> and  <a class="medical medical_review" href="/z/d/html/5740.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Emergency department management"</a> and  <a class="medical medical_review" href="/z/d/html/5748.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Inpatient management"</a> and  <a class="medical medical_review" href="/z/d/html/5747.html" rel="external">"Acute severe asthma exacerbations in children younger than 12 years: Intensive care unit management"</a>.)</p><p>Prophylactic use of SABAs prior to anticipated triggers (eg, exercise, allergen exposure) is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/558.html" rel="external">"Beta agonists in asthma: Acute administration and prophylactic use", section on 'Use in exercise-induced asthma'</a> and  <a class="medical medical_review" href="/z/d/html/533.html" rel="external">"Exercise-induced bronchoconstriction"</a> and  <a class="medical medical_review" href="/z/d/html/558.html" rel="external">"Beta agonists in asthma: Acute administration and prophylactic use", section on 'Allergen-induced asthma'</a>.)</p><p class="headingAnchor" id="H1832319227"><span class="h1">TYPES OF QUICK-RELIEF MEDICATIONS</span><span class="headingEndMark"> — </span>Short-acting beta agonists (SABAs) are the most commonly used medications for the quick relief of acute asthma symptoms [<a href="#rid1">1-3</a>]. Other medications used in select patient populations include a combination of an inhaled glucocorticoid and a rapid-onset, long-acting beta agonist (LABA; eg, <a class="drug drug_pediatric" data-topicid="12959" href="/z/d/drug information/12959.html" rel="external">budesonide-formoterol</a>) and the anticholinergic agent <a class="drug drug_pediatric" data-topicid="13389" href="/z/d/drug information/13389.html" rel="external">ipratropium</a> bromide in combination with a SABA.</p><p class="headingAnchor" id="H4"><span class="h2">Short-acting beta agonists (SABAs)</span></p><p class="headingAnchor" id="H990598483"><span class="h3">Specific preparations</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Racemic </strong><strong>albuterol</strong> – A racemic mixture of <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">albuterol</a> (salbutamol) is the primary SABA used for quick relief of acute asthma symptoms and exacerbations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Levalbuterol</strong> – <a class="drug drug_pediatric" data-topicid="12546" href="/z/d/drug information/12546.html" rel="external">Levalbuterol</a> (Levosalbutamol), the R-enantiomer, is the active isomer of racemic <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">albuterol</a> that confers the bronchodilator effects. Levalbuterol is approved in the United States for treatment of bronchospasm in children ≥4 years of age via hydrofluoroalkane (HFA) metered-dose inhaler (MDI) and ≥6 years of age via solution for nebulization.</p><p></p><p class="bulletIndent1">Available data do not support widespread use of <a class="drug drug_pediatric" data-topicid="12546" href="/z/d/drug information/12546.html" rel="external">levalbuterol</a> instead of racemic <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">albuterol</a> as a quick-relief medication. Some studies have demonstrated favorable efficacy and safety profiles for levalbuterol compared with racemic albuterol, including one in which the hospitalization rate was lower among children who received levalbuterol in the emergency department (ED; 36 versus 45 percent) [<a href="#rid4">4-7</a>]. However, overall clinical studies suggest no meaningful benefits of levalbuterol over racemic albuterol [<a href="#rid8">8-11</a>]. The 2007 National Asthma Education and Prevention Program (NAEPP) guidelines suggest that levalbuterol provides clinically comparable bronchodilation and systemic side effects as racemic albuterol [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other SABAs</strong> – Other SABAs used in the management of childhood asthma include <a class="drug drug_pediatric" data-topicid="12826" href="/z/d/drug information/12826.html" rel="external">terbutaline</a>, clenbuterol, and fenoterol. Inhaled forms of these medications are available in some countries (not the United States), although not all are approved for use in children younger than 12 years.</p><p></p><p class="headingAnchor" id="H8"><span class="h3">Route of delivery</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhaled</strong> – Inhaled SABAs  (<a class="graphic graphic_table graphicRef59229" href="/z/d/graphic/59229.html" rel="external">table 1</a>) have the advantages of lower doses, fewer side effects, and more rapid onset of action than oral agents [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1">Inhaled SABAs are typically administered by an MDI (through a valved holding chamber if an aerosol, but not if an inhalation powder) or by nebulization, along with an infant- or child-sized mask as appropriate for size and developmental age [<a href="#rid13">13</a>]. A number of factors influence the amount of drug actually deposited in the lower airways with either of these methods [<a href="#rid14">14</a>]. In general, administration by MDI is preferred, although this is based upon ED data in which higher doses of SABA are typically used compared with home administration (4 to 12 puffs rather than 2 puffs) [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/5740.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Emergency department management", section on 'Inhaled short-acting beta-2 agonists'</a> and  <a class="medical medical_review" href="/z/d/html/5737.html" rel="external">"Delivery of inhaled medication in children", section on 'Factors affecting drug deposition'</a> and  <a class="medical medical_review" href="/z/d/html/5736.html" rel="external">"Use of medication nebulizers in children"</a> and  <a class="medical medical_review" href="/z/d/html/5738.html" rel="external">"The use of inhaler devices in children"</a>.)</p><p></p><p class="bulletIndent1">A dry powder inhaler (DPI) SABA is also available for children ≥4 years of age [<a href="#rid16">16</a>]. However, it is not known whether an acute exacerbation reduces inspiratory flow enough in this age group to reduce drug delivery when using a DPI. Thus, the authors are comfortable with DPI SABA use for prophylactic treatment prior to exercise in those who can demonstrate proper use of the device but would not advise its use in the acute setting as rescue therapy.</p><p></p><p class="bulletIndent1">It is important for patients who use inhalers to know how to tell when the inhaler is near empty to ensure that they will have access to bronchodilator therapy during an acute exacerbation. Many MDIs now have a built-in counter. Patients should only use the actuator supplied with the MDI (if they have more than one SABA inhaler, such as one for home and one for camp or school) to ensure that the count is accurate. (See  <a class="medical medical_review" href="/z/d/html/5738.html" rel="external">"The use of inhaler devices in children", section on 'Determining when an MDI is empty'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral</strong> – Oral beta agonists (<a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">albuterol</a>) are no longer used for quick-relief treatment because they have more frequent and greater systemic effects, such as tachycardia, tremor, and behavioral and sleep disturbance, and a slower onset of action compared with inhaled SABAs.</p><p></p><p class="headingAnchor" id="H1152678"><span class="h3">Dosing</span><span class="headingEndMark"> — </span>The usual doses of inhaled SABAs used for intermittent asthma symptoms are reviewed in the table  (<a class="graphic graphic_table graphicRef59229" href="/z/d/graphic/59229.html" rel="external">table 1</a>). Higher doses with shorter dosing intervals are often used for more significant acute asthma exacerbations, particularly when administered in the ED or inpatient setting  (<a class="graphic graphic_table graphicRef134102" href="/z/d/graphic/134102.html" rel="external">table 2</a>)<em>.</em> Uses of SABAs in these settings is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/91328.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Overview of home/office management and severity assessment", section on 'Home management'</a> and  <a class="medical medical_review" href="/z/d/html/91328.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Overview of home/office management and severity assessment", section on 'Outpatient management'</a> and  <a class="medical medical_review" href="/z/d/html/5748.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Inpatient management", section on 'Management of bronchospasm'</a> and  <a class="medical medical_review" href="/z/d/html/5740.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Emergency department management", section on 'Inhaled short-acting beta-2 agonists'</a>.)</p><p>Use of SABAs for exercise-induced bronchoconstriction is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/558.html" rel="external">"Beta agonists in asthma: Acute administration and prophylactic use", section on 'Use in exercise-induced asthma'</a> and  <a class="medical medical_review" href="/z/d/html/533.html" rel="external">"Exercise-induced bronchoconstriction", section on 'Pre-exercise treatments for EIB'</a>.)</p><p class="headingAnchor" id="H1171911809"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>The most common side effects are tremor, increased heart rate, and palpitations. SABAs should not be prescribed on a regular schedule, because of concerns about a possible relationship between the frequent use of these agents and deteriorating asthma control [<a href="#rid1">1,17</a>]. In addition, scheduled use prevents assessment of frequency of need based upon signs and symptoms, an important element in evaluating the status of an exacerbation. Decreased sensitivity or tolerance to beta agonists with chronic use (tachyphylaxis) is primarily mediated by downregulation of beta-2 adrenergic receptors. Various factors associated with bronchodilator unresponsiveness include genetics [<a href="#rid18">18</a>], obesity [<a href="#rid19">19</a>], and stress [<a href="#rid20">20</a>]. Beta agonist toxicity and tolerance are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/558.html" rel="external">"Beta agonists in asthma: Acute administration and prophylactic use", section on 'Adverse effects'</a> and  <a class="medical medical_review" href="/z/d/html/558.html" rel="external">"Beta agonists in asthma: Acute administration and prophylactic use", section on 'Tolerance'</a> and  <a class="medical medical_review" href="/z/d/html/544.html" rel="external">"Severe asthma phenotypes", section on 'Asthma associated with obesity'</a> and  <a class="medical medical_review" href="/z/d/html/561.html" rel="external">"Genetics of asthma"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Combination inhaled glucocorticoid and beta agonist</span><span class="headingEndMark"> — </span>Clinical studies have shown that use of inhaled glucocorticoids in conjunction with beta agonists in patients with acute severe asthma can enhance bronchodilator response to beta agonists by reversing beta receptor desensitization and downregulation [<a href="#rid21">21</a>]. In a reciprocal manner, beta agonists influence the activated glucocorticoid receptors. These findings have led to the use of inhaled glucocorticoids with a SABA or a rapid-onset LABA for acute symptoms in select patient populations with asthma. The inhaled glucocorticoid  (<a class="graphic graphic_table graphicRef68517" href="/z/d/graphic/68517.html" rel="external">table 3</a>) and SABA  (<a class="graphic graphic_table graphicRef59229" href="/z/d/graphic/59229.html" rel="external">table 1</a>) are used at standard doses. The LABA most extensively studied for single maintenance and reliever therapy (SMART) is <a class="drug drug_pediatric" data-topicid="13324" href="/z/d/drug information/13324.html" rel="external">formoterol</a>, which has a rapid onset of action and a maximum daily dose that allows for more than twice a day use. The maximum daily dose of formoterol in children 4 to 11 years of age is 36 micrograms, equivalent to 8 puffs of <a class="drug drug_pediatric" data-topicid="12959" href="/z/d/drug information/12959.html" rel="external">budesonide-formoterol</a> MDI. While this dosing is off label, it is supported by national and international guidelines and clinical trials  (<a class="graphic graphic_table graphicRef127785 graphicRef127786" href="/z/d/graphic/127785.html" rel="external">table 4A-B</a>) [<a href="#rid2">2,3</a>] (see <a class="local">'Acute symptoms in patients with persistent asthma'</a> below). Other inhaled glucocorticoid-formoterol combinations that are available in some countries but that have not been studied or approved for SMART and have slightly higher doses of formoterol are <a class="drug drug_pediatric" data-topicid="17070" href="/z/d/drug information/17070.html" rel="external">mometasone-formoterol</a> and beclomethasone-formoterol. Adverse effects from inhaled glucocorticoids are infrequent with intermittent use. The adverse effects of inhaled glucocorticoids are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/548.html" rel="external">"Molecular effects of inhaled glucocorticoid therapy in asthma", section on 'Beta 2-receptor effects'</a> and  <a class="medical medical_review" href="/z/d/html/540.html" rel="external">"Major side effects of inhaled glucocorticoids"</a>.)</p><p class="headingAnchor" id="H3542220489"><span class="h2">Ipratropium bromide</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="13389" href="/z/d/drug information/13389.html" rel="external">Ipratropium</a> bromide is an anticholinergic drug that provides bronchodilation through smooth muscle relaxation [<a href="#rid22">22</a>]. However, it has a slower onset of action than SABAs. It begins to work within 15 to 30 minutes, with a maximum effect seen within one to two hours. Inhaled anticholinergics used on their own are less effective than inhaled beta agonists used alone or in combination with anticholinergics [<a href="#rid23">23</a>]. Ipratropium can be administered via MDI and spacer or via nebulizer. Potential adverse effects of ipratropium bromide include drying of the mouth, blurred vision, urinary retention, tachycardia, and central nervous system effects. Ipratropium is commonly used in combination with a SABA for asthma exacerbations treated in the ED. It is occasionally used in combination with <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">albuterol</a> for quick relief of acute symptoms in patients with asthma who have demonstrated a prior favorable response. (See  <a class="medical medical_review" href="/z/d/html/5740.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Emergency department management", section on 'Ipratropium bromide'</a>.)</p><p class="headingAnchor" id="H263730205"><span class="h2">Nonstandard therapies</span><span class="headingEndMark"> — </span>Experimental and alternative therapies, including over-the-counter products such as homeopathic treatments [<a href="#rid24">24</a>] and racemic <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> inhalers [<a href="#rid25">25-27</a>], are not recommended for routine care of acute asthma symptoms. These therapies are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/528.html" rel="external">"Acute exacerbations of asthma in adults: Home and office management", section on 'Risks associated with inhaled epinephrine'</a> and  <a class="medical medical_review" href="/z/d/html/526.html" rel="external">"Investigational agents for asthma"</a> and  <a class="medical medical_review" href="/z/d/html/104252.html" rel="external">"Complementary, alternative, and integrative therapies for asthma"</a>.)</p><p class="headingAnchor" id="H3751372447"><span class="h1">QUICK-RELIEF TREATMENT</span></p><p class="headingAnchor" id="H210469287"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Short-acting beta agonists (SABAs) such as <a class="drug drug_pediatric" data-topicid="13290" href="/z/d/drug information/13290.html" rel="external">albuterol</a> (salbutamol) and <a class="drug drug_pediatric" data-topicid="12546" href="/z/d/drug information/12546.html" rel="external">levalbuterol</a> (levosalbutamol) remain a cornerstone of the treatment of childhood asthma  (<a class="graphic graphic_table graphicRef127785 graphicRef127786" href="/z/d/graphic/127785.html" rel="external">table 4A-B</a>) [<a href="#rid1">1-3</a>]. SABAs relax airway smooth muscle, reducing constriction, which leads to a prompt increase in airflow [<a href="#rid28">28-33</a>]. These drugs generally provide rapid relief of acute asthma symptoms (eg, coughing, wheezing, chest tightness, and shortness of breath), with a time to onset of action of approximately 5 to 10 minutes, peak effect beginning within approximately 50 minutes, and duration of action of approximately three to six hours. SABAs are the standard emergency treatment for acute asthma exacerbations in all patients based upon adult data, a few early trials in children, and many ensuing years of clinical use. By extrapolation, as-needed use of these drugs is also the primary therapy for acute symptoms in patients with intermittent asthma. (See  <a class="medical medical_review" href="/z/d/html/558.html" rel="external">"Beta agonists in asthma: Acute administration and prophylactic use"</a> and  <a class="medical medical_review" href="/z/d/html/5740.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Emergency department management", section on 'Inhaled short-acting beta-2 agonists'</a>.)</p><p class="headingAnchor" id="H1541239857"><span class="h2">Acute symptoms in patients with intermittent asthma/wheezing</span><span class="headingEndMark"> — </span>We suggest a SABA as needed for acute symptoms in all children with intermittent asthma  (<a class="graphic graphic_table graphicRef127785 graphicRef127786" href="/z/d/graphic/127785.html" rel="external">table 4A-B</a>) [<a href="#rid1">1-3</a>]. Taking a low-dose inhaled glucocorticoid whenever a SABA is used is an alternative to a SABA alone in children &gt;5 years of age. A short course of a high-dose inhaled glucocorticoid starting at the onset of a respiratory illness for 7 to 10 days in addition to a SABA as needed may be used in patients ≤4 years of age with intermittent virus-induced wheezing. This approach to treatment of recurrent virus-induced wheezing in young children is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/546.html" rel="external">"Treatment of recurrent virus-induced wheezing in young children", section on 'Episodic therapy'</a>.)</p><p class="headingAnchor" id="H2403629865"><span class="h2">Acute symptoms in patients with persistent asthma</span><span class="headingEndMark"> — </span>We recommend an as-needed SABA for quick-relief therapy in the following patients  (<a class="graphic graphic_table graphicRef127785 graphicRef127786" href="/z/d/graphic/127785.html" rel="external">table 4A-B</a>) [<a href="#rid1">1-3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Children &lt;4 years of age with any severity of persistent asthma</p><p class="bulletIndent1"><span class="glyph">●</span>Children 4 to 11 years of age with mild persistent asthma</p><p class="bulletIndent1"><span class="glyph">●</span>Children 4 to 11 years of age with severe persistent asthma on step 5 or step 6 therapy</p><p></p><p>For children ≥4 years of age with moderate-to-severe persistent asthma on step 3 or step 4 therapy, we suggest an inhaled glucocorticoid combined with a rapid-onset long-acting beta agonist (LABA; eg, <a class="drug drug_pediatric" data-topicid="13324" href="/z/d/drug information/13324.html" rel="external">formoterol</a>) for both daily and quick-relief therapy (single maintenance and reliever therapy [SMART]) rather than a SABA for quick-relief therapy. The goal of SMART is to both treat acute symptoms and prevent exacerbations. It is reasonable to continue a SABA for quick-relief therapy in patients whose asthma is adequately controlled on a daily combination inhaled glucocorticoid-LABA.</p><p>The recommendations for SMART are largely based upon adolescent and adult data. One post-hoc analysis of data from a larger randomized trial that included 341 children 4 to 11 years of age (118 on <a class="drug drug_pediatric" data-topicid="12959" href="/z/d/drug information/12959.html" rel="external">budesonide-formoterol</a> 80-4.5 microg once daily with up to seven additional quick-relief puffs daily [SMART]; 117 on budesonide-formoterol 80-4.5 microg once daily with a SABA, <a class="drug drug_pediatric" data-topicid="12826" href="/z/d/drug information/12826.html" rel="external">terbutaline</a>, as needed for quick relief; and 106 on <a class="drug drug_pediatric" data-topicid="13096" href="/z/d/drug information/13096.html" rel="external">budesonide</a> 320 microg daily with terbutaline for quick relief) was performed [<a href="#rid34">34,35</a>]. Compared with the other treatment groups, children on SMART had fewer exacerbations (14 versus 38 and 26 percent, respectively) and courses of oral glucocorticoids (0.05 versus 0.3 and 0.25 courses/year, respectively), as well as a longer time to first severe exacerbation. Growth was also significantly better in the two groups of children on budesonide-formoterol versus the higher daily dose of budesonide (approximately 1 cm adjusted mean difference in growth). (See  <a class="medical medical_review" href="/z/d/html/527.html" rel="external">"Initiating asthma therapy and monitoring in adolescents and adults", section on 'Low-dose maintenance and reliever therapy (MART)'</a> and  <a class="medical medical_review" href="/z/d/html/527.html" rel="external">"Initiating asthma therapy and monitoring in adolescents and adults", section on 'Preferred options'</a> and  <a class="medical medical_review" href="/z/d/html/532.html" rel="external">"Ongoing monitoring and titration of asthma therapies in adolescents and adults", section on 'Increasing (stepping up) therapy, for persistent poor symptom control'</a>.)</p><p class="headingAnchor" id="H854002478"><span class="h2">Acute exacerbations</span><span class="headingEndMark"> — </span>The initial at-home approach to treatment of acute exacerbations is similar to that for isolated acute symptoms outlined above. Home management of more significant symptoms associated with an asthma exacerbation are reviewed in detail separately. The outpatient, emergency department (ED), and hospital management of acute asthma exacerbations in children are also discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/91328.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Overview of home/office management and severity assessment"</a> and  <a class="medical medical_review" href="/z/d/html/5740.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Emergency department management"</a> and  <a class="medical medical_review" href="/z/d/html/5748.html" rel="external">"Acute asthma exacerbations in children younger than 12 years: Inpatient management"</a> and  <a class="medical medical_review" href="/z/d/html/5747.html" rel="external">"Acute severe asthma exacerbations in children younger than 12 years: Intensive care unit management"</a>.)</p><p class="headingAnchor" id="H25683356"><span class="h2">Prophylaxis</span><span class="headingEndMark"> — </span>SABAs can be used preventively in patients with well-controlled asthma who have symptoms with exercise and/or allergen exposure. An alternative in adolescents and adults is a combination inhaled glucocorticoid and rapid-onset LABA, but this option has not been adequately studied in younger children. LABAs should not be used as monotherapy. <a class="drug drug_pediatric" data-topicid="13389" href="/z/d/drug information/13389.html" rel="external">Ipratropium</a> is generally not used due to its slower onset of action. Prophylactic use of SABAs prior to anticipated triggers (eg, exercise, allergen exposure) is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/558.html" rel="external">"Beta agonists in asthma: Acute administration and prophylactic use", section on 'Use in exercise-induced asthma'</a> and  <a class="medical medical_review" href="/z/d/html/533.html" rel="external">"Exercise-induced bronchoconstriction", section on 'Pre-exercise treatments for EIB'</a> and  <a class="medical medical_review" href="/z/d/html/558.html" rel="external">"Beta agonists in asthma: Acute administration and prophylactic use", section on 'Allergen-induced asthma'</a>.)</p><p class="headingAnchor" id="H2241599498"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113453.html" rel="external">"Society guideline links: Asthma in children"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15344.html" rel="external">"Patient education: Asthma in children (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16115.html" rel="external">"Patient education: How to use your child's metered dose inhaler (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/1172.html" rel="external">"Patient education: Asthma treatment in children (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Roles and types of quick-relief asthma medications</strong> – Quick-relief medications are primarily taken to relieve the bronchoconstriction that occurs with acute asthma symptoms, although some agents may have additional effects. The most commonly used quick-relief agents are a short-acting beta agonist (SABA) alone, a SABA plus an inhaled glucocorticoid, and a rapid-onset long-acting beta agonist (LABA) in combination with an inhaled glucocorticoid. (See <a class="local">'Introduction'</a> above and <a class="local">'Types of quick-relief medications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Short-acting beta agonists</strong> – Inhaled SABAs are the mainstay of management of acute asthma symptoms and exacerbations  (<a class="graphic graphic_table graphicRef59229" href="/z/d/graphic/59229.html" rel="external">table 1</a>). These drugs generally provide rapid relief of acute asthma symptoms (eg, coughing, wheezing, chest tightness, and shortness of breath). (See <a class="local">'Short-acting beta agonists (SABAs)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combined glucocorticoids and beta agonists</strong> – Inhaled glucocorticoids and beta agonists work in a reciprocal manner, enhancing the response to the other drug when used concomitantly. (See <a class="local">'Combination inhaled glucocorticoid and beta agonist'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to quick-relief therapy</strong> – Our suggested approach to providing quick-relief (rescue) therapy for children with asthma is as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Moderate-to-severe persistent asthma</strong> – For children 4 to 11 years of age with moderate-to-severe persistent asthma on step 3 or step 4 therapy, we suggest an inhaled glucocorticoid combined with a rapid-onset LABA (eg, <a class="drug drug_pediatric" data-topicid="13324" href="/z/d/drug information/13324.html" rel="external">formoterol</a>) for both daily and quick-relief therapy (single maintenance and reliever therapy [SMART]) rather than a SABA for quick-relief therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For children 4 to 11 years of age with severe persistent asthma on step 5 or 6 therapy, we suggest a SABA for quick-relief therapy rather than SMART (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Acute symptoms in patients with persistent asthma'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intermittent and mild persistent asthma</strong> – For most children with less severe asthma (step 1 or step 2) who require quick-relief (rescue) medication, we suggest treatment with a SABA alone rather than in combination with an inhaled glucocorticoid (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Taking a low-dose inhaled glucocorticoid whenever a SABA is used is an alternative to a SABA alone in children &gt;5 years of age who are not on daily controller therapy. (See <a class="local">'Acute symptoms in patients with persistent asthma'</a> above and <a class="local">'Acute symptoms in patients with intermittent asthma/wheezing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Young children with intermittent virus-induced wheezing</strong> - In young children (≤4 years old) with intermittent virus-induced wheezing, a short course of a high-dose inhaled glucocorticoid may be used starting at the onset of a respiratory illness in addition to as-needed SABA. This is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/546.html" rel="external">"Treatment of recurrent virus-induced wheezing in young children", section on 'Intermittent preventive therapy'</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">National Asthma Education and Prevention Program: Expert Panel Report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD. National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on September 19, 2018).</li><li class="breakAll">2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines (Accessed on January 25, 2021).</li><li class="breakAll">Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention: 2020 update. https://ginasthma.org/gina-reports/ (Accessed on September 23, 2020).</li><li><a class="nounderline abstract_t">Gawchik SM, Saccar CL, Noonan M, et al. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol 1999; 103:615.</a></li><li><a class="nounderline abstract_t">Handley DA, Tinkelman D, Noonan M, et al. Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma. J Asthma 2000; 37:319.</a></li><li><a class="nounderline abstract_t">Nelson HS, Bensch G, Pleskow WW, et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol 1998; 102:943.</a></li><li><a class="nounderline abstract_t">Carl JC, Myers TR, Kirchner HL, Kercsmar CM. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr 2003; 143:731.</a></li><li><a class="nounderline abstract_t">Lötvall J, Palmqvist M, Arvidsson P, et al. The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol 2001; 108:726.</a></li><li><a class="nounderline abstract_t">Hardasmalani MD, DeBari V, Bithoney WG, Gold N. Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children. Pediatr Emerg Care 2005; 21:415.</a></li><li><a class="nounderline abstract_t">Qureshi F, Zaritsky A, Welch C, et al. Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. Ann Emerg Med 2005; 46:29.</a></li><li><a class="nounderline abstract_t">Ameredes BT, Calhoun WJ. Levalbuterol versus albuterol. Curr Allergy Asthma Rep 2009; 9:401.</a></li><li><a class="nounderline abstract_t">Larson S, Svedmyr N. Bronchodilating effects and side effects of beta-2-adrenostimulants by different routes of administration. Am Rev Respir Dis 1972; 116:861.</a></li><li><a class="nounderline abstract_t">Conner WT, Dolovich MB, Frame RA, Newhouse MT. Reliable salbutamol administration in 6- to 36-month-old children by means of a metered dose inhaler and Aerochamber with mask. Pediatr Pulmonol 1989; 6:263.</a></li><li><a class="nounderline abstract_t">Whelan AM, Hahn NW. Optimizing drug delivery from metered-dose inhalers. DICP 1991; 25:638.</a></li><li><a class="nounderline abstract_t">Cates CJ, Welsh EJ, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 2013; :CD000052.</a></li><li class="breakAll">Albuterol dry powder inhaler FDA approval for children ages 4 to 11 years. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/205636Orig1s004ltr.pdf.</li><li><a class="nounderline abstract_t">Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364:1505.</a></li><li><a class="nounderline abstract_t">Ortega VE, Meyers DA, Bleecker ER. Asthma pharmacogenetics and the development of genetic profiles for personalized medicine. Pharmgenomics Pers Med 2015; 8:9.</a></li><li><a class="nounderline abstract_t">McGarry ME, Castellanos E, Thakur N, et al. Obesity and bronchodilator response in black and Hispanic children and adolescents with asthma. Chest 2015; 147:1591.</a></li><li><a class="nounderline abstract_t">Brehm JM, Ramratnam SK, Tse SM, et al. Stress and Bronchodilator Response in Children with Asthma. Am J Respir Crit Care Med 2015; 192:47.</a></li><li><a class="nounderline abstract_t">Taylor DR, Hancox RJ. Interactions between corticosteroids and beta agonists. Thorax 2000; 55:595.</a></li><li><a class="nounderline abstract_t">Jones CA, Madison JM, Tom-Moy M, Brown JK. Muscarinic cholinergic inhibition of adenylate cyclase in airway smooth muscle. Am J Physiol 1987; 253:C97.</a></li><li><a class="nounderline abstract_t">Teoh L, Cates CJ, Hurwitz M, et al. Anticholinergic therapy for acute asthma in children. Cochrane Database Syst Rev 2012; :CD003797.</a></li><li class="breakAll">Over-the-Counter Asthma Products Labeled as Homeopathic: FDA Statement - Consumer Warning About Potential Health Risks. http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm439014.htm.</li><li class="breakAll">Safety Concerns with Asthmanefrin and the EZ Breathe Atomizer. http://www.fda.gov/Drugs/DrugSafety/ucm370483.htm.</li><li class="breakAll">Canadian Society of Allergy and Clinical Immunology: Non-prescription availability of theophylline, epinephrine and ephedrine for asthma. http://csaci.ca/index.php?page=359.</li><li><a class="nounderline abstract_t">Mondal P, Kandala B, Ahrens R, et al. Nonprescription racemic epinephrine for asthma. J Allergy Clin Immunol Pract 2014; 2:575.</a></li><li><a class="nounderline abstract_t">Camargo CA Jr, Spooner CH, Rowe BH. Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database Syst Rev 2003; :CD001115.</a></li><li><a class="nounderline abstract_t">Karpel JP, Aldrich TK, Prezant DJ, et al. Emergency treatment of acute asthma with albuterol metered-dose inhaler plus holding chamber: how often should treatments be administered? Chest 1997; 112:348.</a></li><li><a class="nounderline abstract_t">Rudnitsky GS, Eberlein RS, Schoffstall JM, et al. Comparison of intermittent and continuously nebulized albuterol for treatment of asthma in an urban emergency department. Ann Emerg Med 1993; 22:1842.</a></li><li><a class="nounderline abstract_t">Lin RY, Sauter D, Newman T, et al. Continuous versus intermittent albuterol nebulization in the treatment of acute asthma. Ann Emerg Med 1993; 22:1847.</a></li><li><a class="nounderline abstract_t">Ben-Zvi Z, Lam C, Hoffman J, et al. An evaluation of the initial treatment of acute asthma. Pediatrics 1982; 70:348.</a></li><li><a class="nounderline abstract_t">Rossing TH, Fanta CH, Goldstein DH, et al. Emergency therapy of asthma: comparison of the acute effects of parenteral and inhaled sympathomimetics and infused aminophylline. Am Rev Respir Dis 1980; 122:365.</a></li><li><a class="nounderline abstract_t">O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171:129.</a></li><li><a class="nounderline abstract_t">Bisgaard H, Le Roux P, Bjåmer D, et al. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest 2006; 130:1733.</a></li></ol></div><div id="topicVersionRevision">Topic 5743 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : National Asthma Education and Prevention Program: Expert Panel Report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD. National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on September 19, 2018).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines (Accessed on January 25, 2021).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://ginasthma.org/gina-reports/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention: 2020 update. https://ginasthma.org/gina-reports/ (Accessed on September 23, 2020).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10200010" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10883742" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9847435" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14657817" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Comparison of racemic albuterol and levalbuterol for treatment of acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11692096" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16027572" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15988423" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19671384" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Levalbuterol versus albuterol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Bronchodilating effects and side effects of beta-2-adrenostimulants by different routes of administration</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2748223" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Reliable salbutamol administration in 6- to 36-month-old children by means of a metered dose inhaler and Aerochamber with mask.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1877274" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Optimizing drug delivery from metered-dose inhalers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24037768" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24037768" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15500895" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25691813" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Asthma pharmacogenetics and the development of genetic profiles for personalized medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25742612" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Obesity and bronchodilator response in black and Hispanic children and adolescents with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25918834" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Stress and Bronchodilator Response in Children with Asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10856321" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Interactions between corticosteroids and beta agonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3605331" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Muscarinic cholinergic inhibition of adenylate cyclase in airway smooth muscle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22513916" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Anticholinergic therapy for acute asthma in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22513916" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Anticholinergic therapy for acute asthma in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22513916" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Anticholinergic therapy for acute asthma in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22513916" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Anticholinergic therapy for acute asthma in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25213051" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Nonprescription racemic epinephrine for asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14583926" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Continuous versus intermittent beta-agonists in the treatment of acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9266868" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Emergency treatment of acute asthma with albuterol metered-dose inhaler plus holding chamber: how often should treatments be administered?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8239105" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Comparison of intermittent and continuously nebulized albuterol for treatment of asthma in an urban emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8239106" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Continuous versus intermittent albuterol nebulization in the treatment of acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7110806" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : An evaluation of the initial treatment of acute asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7416612" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Emergency therapy of asthma: comparison of the acute effects of parenteral and inhaled sympathomimetics and infused aminophylline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15502112" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17166990" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
